Table 2.
Main pharmacokinetic characteristics of BLIs and their beta-lactam companion for comparison.
| Drug | CL 1 (L/h) | Vd (L) | t1/2 (h) | PPB (%) | References |
|---|---|---|---|---|---|
| AVI | 1.59 | 18.0 | 2.0 | 8 | [45] |
| CAZ | 1.54 | 22.0 | 2.0 | 10 | [45] |
| AZT | 140 | 29.4 | 1.7 | 77 | [46,47] |
| CEF | 1.8–3.0 | 28.3 | 2.5 | 20 | [48] |
| VAB | 10.5 | 19.0 | 2.25 | 33 | [34,49,50] |
| MER | 7.7 | 21.0 | 2.30 | 2 | [34,49,50] |
| REL | 8.1 | 21 | 1.7 | 22 | [34,51] |
| IMI | 8.4 | 21.7 | 1.1 | 20 | [35,51,52] |
| DUR | 10.3 | 31.6 | 2.5 | - | [52] |
| SUL | 2.4 | 12.0 | 1.8 | 38 | [52,53] |
| ZID | 7.4 | 17.4 | 1.9 | <15 | [54] |
| NAC | 8.8 | 20.6 | 2.4 | - | [55] |
| TAN | 5.8 | 30–50 | 6.5 | - | [56,57] |
1 Abbreviations: ATM, aztreonam; AVI, avibactam; AZT, aztreonam; CAZ, ceftazidime; CEF, ceftaroline fosamil; DUR, durlobactam; IMI, imipenem; MER, meropenem; NAC, nacubactam; REL, relebactam; SUL, sulbactam; TAN; taniborbactam; VAB, vaborbactam; ZID, zidebactam; CL, clearance; Vd, volume of distribution; t1/2, terminal elimination half-life; PPB, plasma protein binding.